NCT04592874Phase 2Completed

A Phase 2 Study to Evaluate Efficacy and Safety of AL002 in Participants With Early Alzheimer's Disease

Compare the available registry edits below. Primary completion is the date data collection ends for the main study measures; it does not tell you when results will be published.

Open ClinicalTrials.gov record CSV export · Pro

Primary completion2024-08-19Actual

Enrollment · participants356Actual

Source updated2025-10-29Last update listed in the registry record

Version history

Changes to this trial

Last 12 months

Pro unlocks the full available history and CSV export. View Pro features

Posted 2025-10-02 · 2 fields changed

Primary outcomes · main study measures

Text edit · unverified significance

− Previous value

measure: Disease Progression as Measured by the CDR-SB

+ Updated value

measure: Disease Progression as Measured by the Clinical Dementia Rating - Sum of Boxes (CDR-SB) Score

The saved outcome text may be shortened. Check the source for full wording.

Enrollment · participant count

Recorded edit

− Previous value

count: 381; type: ACTUAL

+ Updated value

count: 356; type: ACTUAL

Check registry source

Study details

Conditions studied

Alzheimer Disease

Treatments or interventions studied

AL002Drug
PlaceboDrug

Primary outcomes · main study measures

Read the study measures

measure: Disease Progression as Measured by the Clinical Dementia Rating - Sum of Boxes (CDR-SB) Score; description: Change from baseline in Clinical Dementia Rating - Sum of Boxes (CDR-SB) score at Weeks 24, 48, 72 and 96. The CDR-SB is a tool used to measure disease severity in Alzheimer's disease. This scale assesses three domains of cognition and three domains of function. The domains are rated on a 5 point scale in which the higher the score corresponds to greater cognitive impairment. The scale range is from 0 to 18 where 0 is considered normal and 18 indicates severe dementia.; timeFrame: Study completion up to 96 weeks

History coverage

Research sample: selected versions from May 2023 onward plus a preceding baseline where available. Only selected fields were retained; endpoint measures were truncated to 300 characters. This is not complete trial or sponsor history. Daily snapshots begin when collection starts.

How to read this history